C J Langer
Overview
Explore the profile of C J Langer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
447
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paz-Ares L, Spira A, Raben D, Planchard D, Cho B, Ozguroglu M, et al.
Ann Oncol
. 2020 Mar;
31(6):798-806.
PMID: 32209338
Background: In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III non-small-cell lung cancer (NSCLC) patients without progression after...
2.
Bonomi P, Gandara D, Hirsch F, Kerr K, Obasaju C, Paz-Ares L, et al.
Ann Oncol
. 2018 Jun;
29(8):1701-1709.
PMID: 29905778
Background: Upregulated expression and aberrant activation of the epidermal growth-factor receptor (EGFR) are found in lung cancer, making EGFR a relevant target for non-small-cell lung cancer (NSCLC). Treatment with anti-EGFR...
3.
Langer C, Hirsh V, Okamoto I, Lin F, Wan Y, Whiting S, et al.
Br J Cancer
. 2015 Jun;
113(1):20-9.
PMID: 26035702
Background: This analysis compared the quality-adjusted survival and clinical outcomes of albumin-bound paclitaxel+carboplatin (nab-PC) vs solvent-based paclitaxel+carboplatin (sb-PC) as first-line therapy in advanced non-small-cell lung cancer (NSCLC) in older patients....
4.
Socinski M, Langer C, Okamoto I, Hon J, Hirsh V, Dakhil S, et al.
Ann Oncol
. 2012 Nov;
24(2):314-321.
PMID: 23123509
Background: This analysis evaluates safety and efficacy in elderly (≥ 70 years old) versus younger patients enrolled in a phase III advanced non-small-cell lung cancer (NSCLC) trial. Patients And Methods:...
5.
Wakelee H, Dahlberg S, Brahmer J, Schiller J, Perry M, Langer C, et al.
Lung Cancer
. 2012 Jan;
76(3):410-5.
PMID: 22266041
Background: The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex. Patients And Methods: Eligible patients (N=1590) from E1594, a 4-arm platinum-based...
6.
Gualberto A, Hixon M, Karp D, Li D, Green S, Dolled-Filhart M, et al.
Br J Cancer
. 2010 Nov;
104(1):68-74.
PMID: 21102589
Background: Phase III trials of the anti-insulin-like growth factor type 1 receptor (IGF-IR) antibody figitumumab (F) in unselected non-small-cell lung cancer (NSCLC) patients were recently discontinued owing to futility. Here,...
7.
Movsas B, Hudes R, Schol J, Mellenson M, Rosvold E, Nicolaou N, et al.
Clin Lung Cancer
. 2003 Dec;
3(2):125-32.
PMID: 14659027
The paclitaxel/carboplatin combination has demonstrated promising activity in metastatic non-small-cell lung cancer (NSCLC); therefore, we mounted an exploratory study of these agents with thoracic radiation (TRT) in locally advanced NSCLC....
8.
Langer C
Lung Cancer
. 2001 Oct;
34(2):297-303.
PMID: 11679189
Although 5-FU administered as a single agent in different intravenous bolus schedules has been shown to have minimal activity in non-small cell lung cancer (NSCLC), several lines of experimental evidence...
9.
Langer C, Ruffer J, Rhodes H, Paulus R, Murray K, Movsas B, et al.
Int J Radiat Oncol Biol Phys
. 2001 Aug;
51(1):113-9.
PMID: 11516860
Purpose: Fractionated external beam radiotherapy (EBRT) +/- carmustine (BCNU) is the standard of care for patients with glioblastoma multiforme (GBM), but survival results remain poor. Preclinical studies indicate synergy between...
10.
Langer C
Oncology (Williston Park)
. 2001 Aug;
15(7 Suppl 8):15-21.
PMID: 11497227
Irinotecan (CPT-11, Camptosar), either alone or in combination with cisplatin (Platinol), has demonstrated activity in advanced non-small-cell lung cancer (NSCLC). In single-agent studies, response rates as high as 35% have...